Ad is loading...
AVEAX
Price
$15.27
Change
+$0.30 (+2.00%)
Updated
Nov 22 closing price
RGEBX
Price
$78.32
Change
+$0.45 (+0.58%)
Updated
Nov 22 closing price
Ad is loading...

AVEAX vs RGEBX

Header iconAVEAX vs RGEBX Comparison
Open Charts AVEAX vs RGEBXBanner chart's image
Ave Maria Focused
Price$15.27
Change+$0.30 (+2.00%)
VolumeN/A
CapitalizationN/A
American Funds Growth Fund of Amer R2E
Price$78.32
Change+$0.45 (+0.58%)
VolumeN/A
CapitalizationN/A
AVEAX vs RGEBX Comparison Chart
Loading...
View a ticker or compare two or three
VS
AVEAX vs. RGEBX commentary
Nov 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AVEAX is a Buy and RGEBX is a StrongBuy.

FUNDAMENTALS
Fundamentals
RGEBX has more cash in the bank: 302B vs. AVEAX (56.2M). RGEBX pays higher dividends than AVEAX: RGEBX (0.16) vs AVEAX (0.00). AVEAX was incepted earlier than RGEBX: AVEAX (5 years) vs RGEBX (10 years). RGEBX is a more actively managed with annual turnover of: 31.00 vs. AVEAX (29.00). RGEBX has a lower initial minimum investment than AVEAX: RGEBX (250) vs AVEAX (2500). RGEBX annual gain was more profitable for investors over the last year : 28.03 vs. AVEAX (25.27).
AVEAXRGEBXAVEAX / RGEBX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence5 years10 years-
Gain YTD11.29728.68939%
Front LoadN/AN/A-
Min. Initial Investment25002501,000%
Min. Initial Investment IRAN/AN/A-
Net Assets56.2M302B0%
Annual Yield % from dividends0.000.16-
Returns for 1 year25.2728.0390%
Returns for 3 years0.26-1.15-23%
Returns for 5 yearsN/A53.03-
Returns for 10 yearsN/A65.99-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MDAI1.190.05
+4.39%
Spectral AI
BKD5.480.15
+2.81%
Brookdale Senior Living
WU11.060.20
+1.84%
Western Union Company (The)
CTSH79.540.68
+0.86%
Cognizant Technology Solutions Corp
ALDX4.850.04
+0.83%
Aldeyra Therapeutics